We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Checkmate Pharmaceuticals Inc | NASDAQ:CMPI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.50 | 10.50 | 10.50 | 0 | 01:00:00 |
From Jul 2021 to Jul 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. on Tuesday said it agreed to buy clinical-stage biopharmaceutical company Checkmate Pharmaceuticals Inc. for about $250 million in a deal that bolsters Regeneron's portfolio of diverse and combinable immuno-oncology candidates.
Regeneron said it will pay $10.50 a share in cash for Checkmate, more than four times Monday's closing price of $2.41 for the Cambridge, Mass., company.
Regeneron said Checkmate's lead investigational asset, vidutolimod, is currently being studied in combination with other agents for melanoma, nonmelanoma skin cancers, and head and neck cancer.
The Tarrytown, N.Y., biotechnology company said it expects to complete the acquisition around the middle of the year.
Trading in shares of Checkmate was halted premarket Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 19, 2022 07:32 ET (11:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Checkmate Pharmaceuticals Chart |
1 Month Checkmate Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
